JP7613743B2 - 転移性癌および化学療法抵抗性癌の治療のためのテトラヒドロキノリノ誘導体 - Google Patents

転移性癌および化学療法抵抗性癌の治療のためのテトラヒドロキノリノ誘導体 Download PDF

Info

Publication number
JP7613743B2
JP7613743B2 JP2021505202A JP2021505202A JP7613743B2 JP 7613743 B2 JP7613743 B2 JP 7613743B2 JP 2021505202 A JP2021505202 A JP 2021505202A JP 2021505202 A JP2021505202 A JP 2021505202A JP 7613743 B2 JP7613743 B2 JP 7613743B2
Authority
JP
Japan
Prior art keywords
halo
cancer
alkyl
alkoxy
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021505202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532158A5 (https=
JPWO2020028461A5 (https=
JP2021532158A (ja
Inventor
エスポジート，マーク
カン，イービン
Original Assignee
ザ、トラスティーズ オブ プリンストン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ、トラスティーズ オブ プリンストン ユニバーシティ filed Critical ザ、トラスティーズ オブ プリンストン ユニバーシティ
Publication of JP2021532158A publication Critical patent/JP2021532158A/ja
Publication of JP2021532158A5 publication Critical patent/JP2021532158A5/ja
Publication of JPWO2020028461A5 publication Critical patent/JPWO2020028461A5/ja
Application granted granted Critical
Publication of JP7613743B2 publication Critical patent/JP7613743B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021505202A 2018-07-31 2019-07-31 転移性癌および化学療法抵抗性癌の治療のためのテトラヒドロキノリノ誘導体 Active JP7613743B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712434P 2018-07-31 2018-07-31
US62/712,434 2018-07-31
PCT/US2019/044278 WO2020028461A1 (en) 2018-07-31 2019-07-31 Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

Publications (4)

Publication Number Publication Date
JP2021532158A JP2021532158A (ja) 2021-11-25
JP2021532158A5 JP2021532158A5 (https=) 2022-08-04
JPWO2020028461A5 JPWO2020028461A5 (https=) 2022-08-04
JP7613743B2 true JP7613743B2 (ja) 2025-01-15

Family

ID=67734803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505202A Active JP7613743B2 (ja) 2018-07-31 2019-07-31 転移性癌および化学療法抵抗性癌の治療のためのテトラヒドロキノリノ誘導体

Country Status (8)

Country Link
US (2) US12162855B2 (https=)
EP (1) EP3830079A1 (https=)
JP (1) JP7613743B2 (https=)
CN (1) CN112638881B (https=)
AU (1) AU2019315444B2 (https=)
CA (1) CA3107120A1 (https=)
IL (1) IL280395B2 (https=)
WO (1) WO2020028461A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638881B (zh) 2018-07-31 2025-01-07 普林斯顿大学托管委员会 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
CA3168533A1 (en) * 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
KR102925139B1 (ko) 2021-04-22 2026-02-10 카요테라 인코포레이티드 헤테로시클릭 화합물 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006349902A (ja) 2005-06-15 2006-12-28 Fujifilm Holdings Corp 黒白熱現像感光材料

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60126270A (ja) * 1983-12-14 1985-07-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPS61145162A (ja) * 1984-12-19 1986-07-02 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
DE3701277A1 (de) 1987-01-17 1988-07-28 Boehringer Mannheim Gmbh Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
JPH01319453A (ja) * 1988-06-22 1989-12-25 Wakamoto Pharmaceut Co Ltd 新規ベンゾキノン誘導体
MXPA05012086A (es) 2003-05-12 2006-02-22 Pfizer Prod Inc Inhibidores de benzamida del receptor p2x7.
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
EP2021502A4 (en) * 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
KR102319882B1 (ko) * 2014-02-19 2021-11-03 아비브 테라퓨틱스, 인크. 암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도
WO2015173169A1 (en) 2014-05-12 2015-11-19 Fondazione Istituto Italiano Di Tecnologia Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
RU2743074C2 (ru) 2014-08-01 2021-02-15 Нуэволюшон А/С Соединения, активные по отношению к бромодоменам
CN112638881B (zh) 2018-07-31 2025-01-07 普林斯顿大学托管委员会 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
CA3168533A1 (en) 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
KR102925139B1 (ko) 2021-04-22 2026-02-10 카요테라 인코포레이티드 헤테로시클릭 화합물 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006349902A (ja) 2005-06-15 2006-12-28 Fujifilm Holdings Corp 黒白熱現像感光材料

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CAPLUS（STN）［online］，2003年，CAS 登録番号：635674-82-7
CAPLUS（STN）［online］，2005年，CAS 登録番号：635674-82-7
Huaxue Shiji ，2003年，２５，２２２－２２４
Huaxue Shiji ，2005年，２７，９５－９６
J. Chem. Inf. Model.，2017年，57，1309-1320
Org. Biomol. Chem.，2019年，17，4629-4639
REGISTRY（STN）［online］，2018年07月30日，N-(7-fluoro-1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-4-(tetrahydro-2H-pyran-3-yl)-benzamide他、1210化合物

Also Published As

Publication number Publication date
AU2019315444B2 (en) 2024-10-31
IL280395B2 (en) 2025-04-01
WO2020028461A1 (en) 2020-02-06
CN112638881B (zh) 2025-01-07
CA3107120A1 (en) 2020-02-06
US20210155602A1 (en) 2021-05-27
EP3830079A1 (en) 2021-06-09
US12162855B2 (en) 2024-12-10
CN112638881A (zh) 2021-04-09
JP2021532158A (ja) 2021-11-25
AU2019315444A1 (en) 2021-02-11
IL280395A (en) 2021-03-01
US20250129046A1 (en) 2025-04-24
IL280395B1 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
US20250129046A1 (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
JP5350217B2 (ja) ジアリールチオヒダントイン化合物
US9926290B2 (en) Inhibitors of INV(16) leukemia
JP2017505787A (ja) 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法
US20260014138A1 (en) INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
KR20220163435A (ko) 피라졸릴프로판아미드 화합물 및 전립선암의 치료에서의 그 용도
Wei et al. Discovery of SILA-123 as a highly potent FLT3 inhibitor for the treatment of acute myeloid leukemia with various FLT3 mutations
Li et al. Design and synthesis of thiazole-based hydroxamate histone deacetylase inhibitors with potent antitumor efficacy by inducing apoptosis, pyroptosis and cell cycle arrest
US11459295B2 (en) 2-beta-naphthyl-acetic acid analogs as AKR1C3 inhibitors and methods of using same
JP2022526844A (ja) 筋肉量及び酸化的代謝を増加させるための組成物及び方法
EP4602034A2 (en) Selective modulators of ahr-regulated transcription and method for using such modulators to treat cancer
HK40049062A (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
HK40049062B (zh) 用於治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
US12570661B2 (en) Isoform-specific aldehyde dehydrogenase inhibitors
JP2025521593A (ja) ３βＨＳＤ１阻害剤及び組成物ならびにそれらの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241219

R150 Certificate of patent or registration of utility model

Ref document number: 7613743

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150